semaglutide autoimmune Do Anti-Obesity Medications Benefit Diseases? Ozempic for Autoimmune Disease: UK

Recent lab results are needed

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management but now also licensed for weight management

Having cleared the hurdle as a treatment for diabetes, the FDA then approved semaglutide, marketed as Wegovy, for obesity in 2021, and then in Europe the following year

The researchers caution that patients should not expect GLP-1 drugs to become arthritis treatments anytime soon

Decades of uncomfortable bouts of irritable bowel syndrome relieved

After the release of Ozempic, the interest in these drugs skyrocketed due to their high effectiveness in treating obesity, even though it is considered off-label use if not used for T2DM or cardiovascular diseases [28]